All In Biotech

Drug Trial Radar · NCT07622810

BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

BALANCE-OBS: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 352 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

352

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Carnot LaboratoriesIndustry
Sponsor type
Industry
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity. It will also evaluate the effects of treatment on metabolic parameters, cardiovascular risk factors, and quality of life. The main questions it aims to answer are: Does Bofanglutide (GZR18) reduce body weight after 36 weeks of treatment compared with Semaglutide? What effects does Bofanglutide (GZR18) have on metabolic parameters, cardiovascular risk factors, and quality of life? How safe and well tolerated is treatment with Bofanglutide (GZR18)? Researchers will compare Bofanglutide (GZR18) with Semaglutide, an active comparator, to evaluate efficacy and safety in adults with overweight or obesity. Participants will: Receive Bofanglutide (GZR18) every 2 weeks or Semaglutide once weekly by subcutaneous injection Follow standardized recommendations for diet and physical activity throughout the study Attend scheduled clinic visits for efficacy and safety assessments Participate in treatment and follow-up for up to 40 weeks, including screening, treatment, and safety follow-up periods

Conditions

  • Obesity & Overweight

Interventions

  • BofanglutidaDrug

    Bofanglutide (GZR18) is a long-acting GLP-1 receptor agonist administered by subcutaneous injection every 2 weeks. Participants will receive progressive dose titration starting at 3 mg up to a target dose of 48 mg according to the study protocol during the 36-week treatment period.

  • SemaglutideDrug

    Semaglutide is a GLP-1 receptor agonist administered by weekly subcutaneous injection with progressive dose titration from 0.25 mg to 1 mg according to the study protocol during the 36-week treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Body Weight From Baseline to Week 36Time frame: Baseline to Week 36

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Instituto Nacional de Cardiología "Ignacio Chávez"

    Mexico City, Mexico

  • Centro de Investigación Clínica y Medicina Traslacional (CIMeT)

    Guadalajara, Jalisco, Mexico

  • CICMEX Centro de Investigación Clínica de México S de RL de CV.

    Morelia, Michoacán, Mexico

  • SMIQ, S. de R.L. de C.V.

    Querétaro City, Querétaro, Mexico

  • Investigación Médica Sonora S.C.

    Hermosillo, Sonora, Mexico

  • Centro de Estudios de lnvestigación Metabólicos y Cardiovasculares, S.C.

    Ciudad Madero, Tamaulipas, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.